AEMD Aethlon Medical Inc: נכסים מצרפיים של הפעילות העסקית

Aethlon Medical (AEMD) is mitigating regulatory risks by diversifying its focus between oncology and viral testing via the Hemopurifier system. This daily price chart for total assets is fixed at 5.77. The company currently lacks pricing power due to the current stage of clinical trials. Nevertheless, the brand is considered a pioneer in extracorporeal purification, maintaining significant weight in critical care medicine thanks to its life-saving filters.

For high-quality stock selection, an investor must evaluate capital density via total assets, which are reverse-calculated here from the ROA to analyze financial stability. In the case of Aethlon Medical (AEMD), this metric reflects the resource base for developing an innovative hemopurifier that removes pathogens, allowing the company's gross assets to be used to forecast its ability to scale this unique blood purification technology.